Income Taxes (Tables)

12 Months Ended

Dec. 31, 2018

Income Tax Disclosure [Abstract]

Schedule of Components of Deferred Tax Assets and Liabilities

Significant components of the Company’s deferred tax assets and liabilities are as follows:

	December 31,
	2018			2017
Deferred tax assets:
Net operating loss carry forwards	$	3,604,179		$	1,843,000
Capitalized research and development costs		14,381,936			12,177,000
Accrued liabilities		232,899			25,000
Tax credit carryforwards		6,311,164			3,286,000
Stock-based compensation		394,918			116,000
Total deferred tax assets		24,925,096			17,447,000
Valuation allowance		(24,922,829	)		(17,444,000	)
Net deferred tax assets		2,267			3,000
Deferred tax liabilities		(2,267	)		(3,000	)
	$	—		$	—

Schedule of Reconciliation of Effective Income Tax Rate

A reconciliation of the United States federal statutory tax rate to the effective tax rate is as follows:

	December 31,
	2018			2017
Federal statutory rate		21.0	%		34.0	%
R&D and Orphan Drug credits		10.9	%		7.6	%
State income tax, net of federal tax benefit		2.8	%		(0.2	%)
Valuation allowance		(35.2	%)		18.2	%
Tax reform impact		0.0	%		(57.8	%)
Other, net		0.5	%		(1.8	%)
Effective tax rate		0.0	%		0.0	%